eISSN: 1644-4124
ISSN: 1426-3912
Central European Journal of Immunology
Current issue Archive Manuscripts accepted About the journal Abstracting and indexing Subscription Contact Instructions for authors
SCImago Journal & Country Rank

2/2018
vol. 43
 
Share:
Share:
more
 
 
abstract:
Experimental immunology

CD40L-adjuvanted DNA vaccine carrying EBV-LMP2 antigen enhances anti-tumor effect in NPC transplantation tumor animal

Lei Lei, Jianhui Li, Meiqing Liu, Xiaoming Hu, Ya Zhou, Shiming Yang

Central European Journal of Immunology 2018; 43(2), 117-122
Online publish date: 2018/06/30
View full text
Get citation
ENW
EndNote
BIB
JabRef, Mendeley
RIS
Papers, Reference Manager, RefWorks, Zotero
AMA
APA
Chicago
Harvard
MLA
Vancouver
 
CD40L, a costimulatory molecule for dendritic cells (DCs) and B cells, can serve as an adjuvant for enhancing the specific immune response induced by DNA vaccine carrying tumor-associated antigens. In this study, we investigated the potential of CD40L as an adjuvant to enhance the anti-tumor effect mediated by a DNA vaccine based on the Epstein-Barr virus-latent membrane protein 2 (EBV-LMP2) antigen. The plasmids capable of expressing the fusion protein EBV-LMP2-CD40L were constructed. Expression vector pVAX1 and plasmid expressing the individual antigen EBV-LMP2 were used as control groups. These plasmids were used to immunize female BALB/c mice (4-6 weeks old) at days 0, 7 and 14. The results suggest that immunization with DNA vaccines carrying fusion gene EBV-LMP2-CD40L can induce specific immunity more effectively than the plasmid expression individual antigen EBV-LMP2. In order to evaluate the anti-tumor effect of this DNA vaccine, we constructed a tumor bearing mouse model. After immunization, the tumor bearing mouse model, DNA vaccination with EBV-LMP2-CD40L plasmid significantly inhibited tumor growth in the tumor bearing mouse model and enhanced the tumor inhibition rate. This study demonstrated that encoding the EBV-LMP2 tumor antigen within an EBV-LMP2-CD40L DNA vaccine generates an effective antitumor response against EBV tumor, which may be a promising method to improve the antitumor immunity of DNA vaccine.
keywords:

CD40L, DNA vaccine, Epstein-Barr virus, nasopharyngeal carcinoma, anti-tumor

references:
Cohen JI (2015): Epstein-barr virus vaccines. Clin Transl Immu­nology 4: e32.
Hutajulu SH, Kurnianda J, Tan IB, Middeldorp JM (2014): Therapeutic implications of Epstein-Barr virus infection for the treatment of nasopharyngeal carcinoma. Ther Clin Risk Manag 10: 721-736.
Lun SW, Cheung ST, Lo KW (2014): Cancer stem-like cells in Epstein-Barr virus-associated nasopharyngeal carcinoma. Chin J Cancer 33: 529-538.
Tsang CM, Deng W, Yip YL, et al. (2014): Epstein-Barr virus infection and persistence in nasopharyngeal epithelial cells. Chin J Cancer 33: 549-555.
Ramayanti O, Juwana H, Verkuijlen SA, et al. (2017): Epstein-Barr virus mRNA profiles and viral DNA methylation status in nasopharyngeal brushings from nasopharyngeal carcinoma patients reflect tumor origin. Int J Cancer 140: 149-162.
Zheng Y, Parsonage G, Zhuang X, et al. (2015): Human Leukocyte Antigen (HLA) A*1101-Restricted Epstein-Barr Virus-Specific T-cell Receptor Gene Transfer to Target Nasopharyngeal Carcinoma. Cancer Immunol Res 3: 1138-1147.
Lin X, Gudgeon NH, Hui EP, et al. (2008): CD4 and CD8 T cell responses to tumour-associated Epstein-Barr virus antigens in nasopharyngeal carcinoma patients. Cancer Immunol Immunother 57: 963-975.
8. Subramaniam DS, Liu SV, Giaccone G. (2016): Novel approaches in cancer immunotherapy. Discov Med 21: 267-274.
Jorritsma SH, Gowans EJ, Grubor-Bauk B, Wijesundara DK (2016): Delivery methods to increase cellular uptake and immunogenicity of DNA vaccines. Vaccine 34: 5488-5494.
Li D, Huang Y, Du Q, et al. (2016): CD40 Ligand and GMCSF Coexpression Enhance the Immune Responses and Protective Efficacy of PCV2 Adenovirus Vaccine. Viral Immunol 29: 148-158.
Barr TA, Carlring J, Heath AW (2006): Co-stimulatory agonists as immunological adjuvants. Vaccine 24: 3399-3407.
Soliman H, Mediavilla-Varela M, Antonia SJ (2015): A GM-CSF and CD40L bystander vaccine is effective in a murine breast cancer model. Breast Cancer (Dove Med Press) 7: 389-397.
Curran KJ, Seinstra BA, Nikhamin Y, et al. (2015): Enhancing antitumor efficacy of chimeric antigen receptor T cells through constitutive CD40L expression. Mol Ther 23: 769-778.
Fabricius D, Breckerbohm L, Vollmer A, et al. (2011): Acute lymphoblastic leukemia cells treated with CpG oligodeoxynucleotides, IL-4 and CD40 ligand facilitate enhanced anti-leukemic CTL responses. Leukemia 25: 1111-1121.
Palumbo RN, Nagarajan L, Wang C. (2011): Recombinant monomeric CD40 ligand for delivering polymer particles to dendritic cells. Biotechnol Prog 27: 830-837.
Papaioannou NE, Beniata OV, Vitsos P, et al. (2016): Harnessing the immune system to improve cancer therapy. Ann Transl Med 44: 261.
Gulley JL, Mulders P, Albers P, et al. (2015): Perspectives on sipuleucel-T: Its role in the prostate cancer treatment paradigm. Oncoimmunology 5: e1107698.
Grunwald T, Ulbert S. (2015): Improvement of DNA vaccination by adjuvants and sophisticated delivery devices: vaccine-platforms for the battle against infectious diseases. Clin Exp Vaccine Res 4: 1-10.
Li L, Petrovsky N (2016): Molecular mechanisms for enhanced DNA vaccine immunogenicity. Expert Rev Vaccines 15: 313-329.
Kwa S, Lai L, Gangadhara S, et al. (2014): CD40L-adjuvanted DNA/modified vaccinia virus Ankara simian immunodeficiency virus SIV239 vaccineenhances SIV-specific humoral and cellular immunity and improves protection against a heterologous SIVE660 mucosal challenge. J Virol 88: 9579-9589.
Younesi V, Nikzamir H, Yousefi M, et al. (2010): Epstein Barr virus inhibits the stimulatory effect of TLR7/8 and TLR9 agonists but not CD40 ligand in human B lymphocytes. Microbiol Immunol 54: 534-541.
Khanna N, Stuehler C, Conrad B, et al. (2011): Generation of a multipathogen-specific T-cell product for adoptive immunotherapy based on activation-dependent expression of CD154. Blood 118: 1121-1131.
Soong RS, Song L, Trieu J, et al. (2014): Direct T cell activation via CD40 ligand generates high avidity CD8+ T cells capable of breaking immunological tolerance for the control of tumors. PLoS One 9: e93162.
Auten MW, Huang W, Dai G, Ramsay AJ (2012): CD40 ligand enhances immunogenicity of vector-based vaccines in immunocompetent and CD4+ T cell deficient individuals. Vaccine 30: 2768-2777.
FEATURED PRODUCTS
Quick links
© 2018 Termedia Sp. z o.o. All rights reserved.
Developed by Bentus.
PayU - płatności internetowe